220 related articles for article (PubMed ID: 31561440)
1. Use of Modified
Beier LS; Rossa J; Woodhouse S; Bergmann S; Kramer HB; Protze J; Eichner M; Piontek A; Vidal-Y-Sy S; Brandner JM; Krause G; Zitzmann N; Piontek J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561440
[TBL] [Abstract][Full Text] [Related]
2. Specific binding of Clostridium perfringens enterotoxin fragment to Claudin-b and modulation of zebrafish epidermal barrier.
Zhang J; Ni C; Yang Z; Piontek A; Chen H; Wang S; Fan Y; Qin Z; Piontek J
Exp Dermatol; 2015 Aug; 24(8):605-10. PubMed ID: 25869230
[TBL] [Abstract][Full Text] [Related]
3. Reversible opening of the blood-brain barrier by claudin-5-binding variants of Clostridium perfringens enterotoxin's claudin-binding domain.
Neuhaus W; Piontek A; Protze J; Eichner M; Mahringer A; Subileau EA; Lee IM; Schulzke JD; Krause G; Piontek J
Biomaterials; 2018 Apr; 161():129-143. PubMed ID: 29421550
[TBL] [Abstract][Full Text] [Related]
4. Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin.
Piontek A; Eichner M; Zwanziger D; Beier LS; Protze J; Walther W; Theurer S; Schmid KW; Führer-Sakel D; Piontek J; Krause G
Mol Oncol; 2020 Feb; 14(2):261-276. PubMed ID: 31825142
[TBL] [Abstract][Full Text] [Related]
5. Claudin targeting as an effective tool for directed barrier modulation of the viable epidermis.
Beier LS; Waldow A; Khomeijani Farahani S; Mannweiler R; Vidal-Y-Sy S; Brandner JM; Piontek J; Günzel D
Ann N Y Acad Sci; 2022 Nov; 1517(1):251-265. PubMed ID: 35994210
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of Clostridium perfringens enterotoxin interaction with claudin-3/-4 protein suggests structural modifications of the toxin to target specific claudins.
Veshnyakova A; Piontek J; Protze J; Waziri N; Heise I; Krause G
J Biol Chem; 2012 Jan; 287(3):1698-708. PubMed ID: 22128179
[TBL] [Abstract][Full Text] [Related]
7. Directed structural modification of Clostridium perfringens enterotoxin to enhance binding to claudin-5.
Protze J; Eichner M; Piontek A; Dinter S; Rossa J; Blecharz KG; Vajkoczy P; Piontek J; Krause G
Cell Mol Life Sci; 2015 Apr; 72(7):1417-32. PubMed ID: 25342221
[TBL] [Abstract][Full Text] [Related]
8. On the interaction of Clostridium perfringens enterotoxin with claudins.
Veshnyakova A; Protze J; Rossa J; Blasig IE; Krause G; Piontek J
Toxins (Basel); 2010 Jun; 2(6):1336-56. PubMed ID: 22069641
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
10. Claudin-9 structures reveal mechanism for toxin-induced gut barrier breakdown.
Vecchio AJ; Stroud RM
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17817-17824. PubMed ID: 31434788
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for
Vecchio AJ; Rathnayake SS; Stroud RM
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876770
[TBL] [Abstract][Full Text] [Related]
12. A cCPE-based xenon biosensor for magnetic resonance imaging of claudin-expressing cells.
Piontek A; Witte C; May Rose H; Eichner M; Protze J; Krause G; Piontek J; Schröder L
Ann N Y Acad Sci; 2017 Jun; 1397(1):195-208. PubMed ID: 28636798
[TBL] [Abstract][Full Text] [Related]
13. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus.
Zheng A; Yuan F; Li Y; Zhu F; Hou P; Li J; Song X; Ding M; Deng H
J Virol; 2007 Nov; 81(22):12465-71. PubMed ID: 17804490
[TBL] [Abstract][Full Text] [Related]
14. Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.
Sekhar V; Pollicino T; Diaz G; Engle RE; Alayli F; Melis M; Kabat J; Tice A; Pomerenke A; Altan-Bonnet N; Zamboni F; Lusso P; Emerson SU; Farci P
PLoS Pathog; 2018 Mar; 14(3):e1006916. PubMed ID: 29538454
[TBL] [Abstract][Full Text] [Related]
15. Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes.
Orlando BJ; Dominik PK; Roy S; Ogbu CP; Erramilli SK; Kossiakoff AA; Vecchio AJ
J Biol Chem; 2022 Sep; 298(9):102357. PubMed ID: 35952760
[TBL] [Abstract][Full Text] [Related]
16. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
[TBL] [Abstract][Full Text] [Related]
17. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
J Virol; 2018 May; 92(10):. PubMed ID: 29491159
[TBL] [Abstract][Full Text] [Related]
18. [Non-invasive drug delivery system with the claudin binder].
Takahashi A; Kondoh M; Yagi K
Yakugaku Zasshi; 2011; 131(11):1583-7. PubMed ID: 22041696
[TBL] [Abstract][Full Text] [Related]
19. A human claudin-1-derived peptide inhibits hepatitis C virus entry.
Si Y; Liu S; Liu X; Jacobs JL; Cheng M; Niu Y; Jin Q; Wang T; Yang W
Hepatology; 2012 Aug; 56(2):507-15. PubMed ID: 22378192
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
